Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab

Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab

Abstract Background Although the standard therapy for advanced-stage hepatocellular carcinoma (HCC) is systemic chemotherapy, the combination of atezolizumab and bevacizumab (atezo + bev) with a high objective response rate may lead to conversion to resection in patients with initially unresectable...

Full description

Bibliographic Details
Main Authors: Masayuki Okuno, Takamichi Ishii, Akihiko Ichida, Akihiko Soyama, Nobuyuki Takemura, Seiko Hirono, Susumu Eguchi, Kiyoshi Hasegawa, Yasuharu Sasaki, Kohei Uemura, Norihiro Kokudo, Etsuro Hatano
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma
Unresectable
Advanced stage
Conversion
Immune checkpoint inhibitor
Online Access:https://doi.org/10.1186/s12885-023-11302-6

Internet

https://doi.org/10.1186/s12885-023-11302-6

Similar Items